Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina. Show more
101 Glen Lennox Drive, Chapel Hill, NC, 27517, United States
Market Cap
503M
52 Wk Range
$5.78 - $19.40
Previous Close
$13.31
Open
$13.50
Volume
2,094,837
Day Range
$13.10 - $14.25
Enterprise Value
507.3M
Cash
118M
Avg Qtr Burn
-14.15M
Insider Ownership
0.11%
Institutional Own.
62.36%
Qtr Updated
06/30/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
TNX-103 (Oral Levosimendan) Details Pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) | Phase 3 Data readout |